ReviewJournal of cellular and molecular medicine2025
A Model of Butyrate Activity and Resistance in CRC.
Review in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Trial
- Cell cycle dysregulation: a central hub in colitis-associated colorectal carcinogenesis.Frontiers in immunology · 2026Review
- Microbiota-host metabolism reprogramming in colorectal cancer: from pathogenesis to precision therapies.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Butyrate, a breakdown product of dietary fibre, may in part mediate the ability of a high-fibre diet to reduce the risk of colorectal cancer (CRC). However, CRC can still develop despite a high-fibre diet; hence, butyrate resistance may influence colonic tumorigenesis. To model butyrate resistance in vitro, butyrate-resistant cells were developed and mechanisms identified by which these cells evade the effects of butyrate. These mechanisms can be interpreted in light of the existing literature to further our understanding of butyrate resistance. The current review integrates findings from various studies from my laboratory on butyrate-resistant cells, in addition to other work in the literature, to present a model of how butyrate-resistant CRC cells balance different signalling outputs to generate the resistant phenotype. Loss of p300 expression in butyrate resistance allows increased noncanonical Wnt signalling to occur without activating differentiation pathways, AKT/PKB survival signalling is activated, and CBP-Wnt activity is maintained in the pro-proliferative range. Further, overexpression of Tcf3 suppresses butyrate-induced Wnt hyperactivation. Other factors, signalling pathways and modifying influences also affect butyrate sensitivity vs. resistance. Understanding the possible role of butyrate resistance will assist in improving chemopreventive strategies for this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.